{"id":"igpro","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Thrombosis (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IgPro is a polyvalent immunoglobulin preparation derived from pooled human plasma that contains a broad spectrum of antibodies against common pathogens. It functions by providing immediate passive immunity and can modulate inflammatory and autoimmune responses through multiple mechanisms including Fc receptor engagement and complement regulation. It is used in patients with primary immunodeficiencies, secondary immunodeficiencies, and certain autoimmune or inflammatory conditions.","oneSentence":"IgPro is an intravenous immunoglobulin (IVIG) product that provides passive immunity by supplying pooled human antibodies to help fight infections and modulate immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:48:00.290Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary immunodeficiency disorders"},{"name":"Secondary immunodeficiency in hematologic malignancies"},{"name":"Chronic inflammatory demyelinating polyneuropathy (CIDP)"},{"name":"Multifocal motor neuropathy"},{"name":"Immune thrombocytopenia (ITP)"}]},"trialDetails":[{"nctId":"NCT07076446","phase":"PHASE4","title":"An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2025-07-15","conditions":"Primary Immunodeficiency","enrollment":8},{"nctId":"NCT00751621","phase":"PHASE3","title":"Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2008-08","conditions":"Primary Immunodeficiency (PID)","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Immune globulin subcutaneous (Human) 20% liquid"],"phase":"marketed","status":"active","brandName":"IgPro","genericName":"IgPro","companyName":"CSL Behring","companyId":"csl-behring","modality":"Biologic","firstApprovalDate":"","aiSummary":"IgPro is an intravenous immunoglobulin (IVIG) product that provides passive immunity by supplying pooled human antibodies to help fight infections and modulate immune responses. Used for Primary immunodeficiency disorders, Secondary immunodeficiency, Autoimmune and inflammatory conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}